1Vincent Obstetrics and Gynecology Department, Division of Female Pelvic Medicine and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA
2Department of Obstetrics, Gynecology & Reproductive Biology, Harvard Medical School, Boston, MA
3Health Decision Sciences Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Address correspondence to: May Wakamatsu, MD, Director, Female Pelvic Medicine & Reconstructive Surgery, 55 Fruit Street, Massachusetts General Hospital, Boston, Founders 4, MA 02114. E-mail: [email protected]
Received 31 August, 2021
Revised 23 September, 2021
Accepted 23 September, 2021
This paper was presented at the Society for Medical Decision Making Annual Conference: October 22, 2019 Portland, OR and at the Massachusetts General Hospital Clinical Research Day: October 3, 2019 Boston, MA.
Funding/support: Financial support for this study was provided entirely by internal department funds through the Massachusetts General Physicians Organization at The Massachusetts General Hospital.
Clinical Trials ID: NCT04369404 https://www.clinicaltrials.gov/ct2/show/NCT04369404?term=Impact+of+Decision+Aids+in+Urogynecology&draw=2&rank=1.
Financial disclosure/conflicts of interest: None reported.
Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's Website (www.menopause.org).